Dr. Clay Siegall is prominent for founding Seattle Genetics, a biotech firm specializing in the creation of targeted therapy drugs made for diseases that have hardly received substantial mortality improvements for decades.
Dr. Siegall is an alumnus of the University of Maryland and George Washington University. He majored in a bachelor of science and later advanced his education to genetics study.
Founding Seattle Genetics
Seattle Genetics was founded in 1998. Since then, Siegall has exuded excellent leadership by leading the company to higher ranks of the targeted therapy industry by developing the first antibody conjugate drug to receive an FDA-Approval. Because of Siegall’s commitment to working for better health standards at Seattle Genetics, the company now owns over thirty drug pipelines through strategic partnerships. These partnerships are with the drug manufacturers who are also equipped with the knowledge needed to provide better treatment methods.
Among the companies that Seattle Genetics has partnered with include Bayer, Genentech, and Pfizer. Moreover, under Clay’s leadership, Seattle Genetics has grown from being a boutique firm to a huge firm with qualified researchers to present actual details on the use of drugs for healthcare needs. And, Clay Siegall is just beginning. He has plans to expand Seattle Genetics by developing unmatched drug portfolios for better partnerships.
The Future of Seattle Genetics
Clay Siegall holds to the belief that cancer treatment and systemic chemotherapies will be extinct in the near future. For that reason, he has invested in targeted therapies as these therapies become the center of providing cancer treatment in medical facilities.
But just how did Clay Siegall venture into the industry of medicine? As a toddler, Clay Siegall always had a passion for medicine. He was keen on the impact of technology in matters of health and overcoming diseases. Faced with a family health issues in which, a close relative was suffering, Clay Siegall became more interested in nature’s course to restore health. He, therefore, joined the University of Maryland for a course in zoology.
The relative’s pain saddened clay during chemotherapy. He made up his mind to ensure that nobody else suffers like the relative did. That is how he ventured into biotechnology. Currently, Seattle Genetics is well positioned to provide modern treatment and therapies.